ArticleNanoscale research letters2019
An Efficient Cell-Targeting Drug Delivery System Based on Aptamer-Modified Mesoporous Silica Nanoparticles.
Article in Nanoscale research letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 74 citations in OpenAlex.
- Properties and Multidisciplinary Applications of Zeolites and Mesoporous Materials.Molecules (Basel, Switzerland) · 2026Article
- PD-L1 Aptamer-Functionalized Mesoporous Silica Nanoparticles for Targeted Doxorubicin Delivery in Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Article
- Review
- Using aptamers for targeted delivery of RNA therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations.Molecules (Basel, Switzerland) · 2025Review
- Bridging Smart Nanosystems with Clinically Relevant Models and Advanced Imaging for Precision Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims.Biosensors · 2024Review
- Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.Biomaterials research · 2023Review
- Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies.Nanoscale advances · 2023Review
- How Key Alterations of Mesoporous Silica Nanoparticles Affect Anti-Lung Cancer Therapy? A Comprehensive Review of the Literature.International journal of nanomedicine · 2023Review
- Effects of morphology and size of nanoscale drug carriers on cellular uptake and internalization process: a review.RSC advances · 2022Review
- Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate.Biomaterials research · 2022Article
- Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy.Pharmaceutics · 2022Review
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?Chemical Society reviews · 2022Review
- Influence of Critical Parameters on Cytotoxicity Induced by Mesoporous Silica Nanoparticles.Nanomaterials (Basel, Switzerland) · 2022Article
- Multivalent Aptamer Approach: Designs, Strategies, and Applications.Micromachines · 2022Review
- Review
- Using magnetic mesoporous silica nanoparticles armed with EpCAM aptamer as an efficient platform for specific delivery of 5-fluorouracil to colorectal cancer cells.Frontiers in bioengineering and biotechnology · 2022Article
- Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
How to deliver chemotherapeutic drugs efficiently and selectively to tumor cells to improve therapeutic efficacy remains a difficult problem. We herein construct an efficient cell-targeting drug delivery system (Sgc8-MSN/Dox) based on aptamer-modified mesoporous silica nanoparticles that relies on the tumor-targeting ability of the aptamer Sgc8 to deliver doxorubicin (Dox) to leukemia cells in a targeted way, thereby improving therapeutic efficacy and reducing toxicity. In this work, Sgc8-MSN/Dox showed sustained Dox release, and they targeted and efficiently killed CCRF-CEM human acute T lymphocyte leukemia cells, suggesting potential as a cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.